Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gregory J Dore

Showing results (351-360 of 404) with videos related to

Pageof 41
Sort By:
Journal of Hepatology|March 1, 2016
Transmission of hepatitis C virus infection among younger and older people who inject drugs in Vancouver, CanadaBrendan Jacka, Tanya Applegate, Art F Poon, et al.
Journal of Viral Hepatitis|November 8, 2019
Hepatitis C virus testing, liver disease assessment and treatment uptake among people who inject drugs pre- and post-universal access to direct-acting antiviral treatment in Australia: The LiveRLife studySahar Bajis, Jason Grebely, Behzad Hajarizadeh, et al.
Journal of Viral Hepatitis|December 23, 2018
Genomic variability of within-host hepatitis C variants in acute infectionChaturaka Rodrigo, Preston Leung, Andrew R Lloyd, et al.
The International Journal on Drug Policy|May 9, 2022
Declining prevalence of current HCV infection and increased treatment uptake among people who inject drugs: The ETHOS Engage studyHeather Valerio, Maryam Alavi, Anna Conway, et al.
The Journal of Infectious Diseases|April 18, 2015
Hepatitis C Virus Reinfection and Spontaneous Clearance of Reinfection--the InC3 StudyRachel Sacks-Davis, Jason Grebely, Gregory J Dore, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|September 27, 2014
Interferon lambda 3 genotype predicts hepatitis C virus RNA levels in early acute infection among people who inject drugs: the InC(3) studyBehzad Hajarizadeh, Bart Grady, Kimberly Page, et al.
Drug and Alcohol Dependence|June 30, 2022
Prevalence and factors associated with hospitalisation for bacterial skin infections among people who inject drugs: The ETHOS Engage StudyAlice Wheeler, Heather Valerio, Evan B Cunningham, et al.
Annals of Internal Medicine|November 10, 2015
Sofosbuvir Plus Velpatasvir Combination Therapy for Treatment-Experienced Patients With Genotype 1 or 3 Hepatitis C Virus Infection: A Randomized TrialStephen Pianko, Steven L Flamm, Mitchell L Shiffman, et al.
Journal of Hepatology|October 27, 2019
Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trialGregory J Dore, Jordan J Feld, Alex Thompson, et al.
The International Journal on Drug Policy|June 19, 2017
Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE studyJason Grebely, Olav Dalgard, Evan B Cunningham, et al.
Pageof 41

Showing results (351-360 of 404) with videos related to

Sort By:
Pageof 41
Journal of Hepatology|March 1, 2016
Transmission of hepatitis C virus infection among younger and older people who inject drugs in Vancouver, CanadaBrendan Jacka, Tanya Applegate, Art F Poon, et al.
Journal of Viral Hepatitis|November 8, 2019
Hepatitis C virus testing, liver disease assessment and treatment uptake among people who inject drugs pre- and post-universal access to direct-acting antiviral treatment in Australia: The LiveRLife studySahar Bajis, Jason Grebely, Behzad Hajarizadeh, et al.
Journal of Viral Hepatitis|December 23, 2018
Genomic variability of within-host hepatitis C variants in acute infectionChaturaka Rodrigo, Preston Leung, Andrew R Lloyd, et al.
The International Journal on Drug Policy|May 9, 2022
Declining prevalence of current HCV infection and increased treatment uptake among people who inject drugs: The ETHOS Engage studyHeather Valerio, Maryam Alavi, Anna Conway, et al.
The Journal of Infectious Diseases|April 18, 2015
Hepatitis C Virus Reinfection and Spontaneous Clearance of Reinfection--the InC3 StudyRachel Sacks-Davis, Jason Grebely, Gregory J Dore, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|September 27, 2014
Interferon lambda 3 genotype predicts hepatitis C virus RNA levels in early acute infection among people who inject drugs: the InC(3) studyBehzad Hajarizadeh, Bart Grady, Kimberly Page, et al.
Drug and Alcohol Dependence|June 30, 2022
Prevalence and factors associated with hospitalisation for bacterial skin infections among people who inject drugs: The ETHOS Engage StudyAlice Wheeler, Heather Valerio, Evan B Cunningham, et al.
Annals of Internal Medicine|November 10, 2015
Sofosbuvir Plus Velpatasvir Combination Therapy for Treatment-Experienced Patients With Genotype 1 or 3 Hepatitis C Virus Infection: A Randomized TrialStephen Pianko, Steven L Flamm, Mitchell L Shiffman, et al.
Journal of Hepatology|October 27, 2019
Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trialGregory J Dore, Jordan J Feld, Alex Thompson, et al.
The International Journal on Drug Policy|June 19, 2017
Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE studyJason Grebely, Olav Dalgard, Evan B Cunningham, et al.
Pageof 41